Clinical Trials Database

Specialty/ Disorder

Study  Information

Purpose

PI Name
/Sponsor

More Information

Contact

Schizophrenia

This study is currently recruiting participants.

Population:
Adults age 18 to 40 

Setting:
Outpatient

This study is seeking volunteers for a clinical trial that may improve cognitive functioning. 

Participants take add-on valacyclovir or placebo for sixteen weeks and are compensated for their time. 

Eligibility:

  • 18 - 40 years old

  • Diagnosed with Schizophrenia or Schizoaffective Disorder within the past eight years

Faith Dickerson, PhD, MPH 

Sheppard Pratt Health System Towson, MD

(Coordinating site: Indiana University)

Click here to visit clinicaltrials.gov for more information

Cassie Stallings, R.N. or call 410-938-4356 

Schizophrenia

This study is currently recruiting participants.

Population:
Adults age 18 to 68

Setting:
Outpatient 

This study is seeking volunteers who experience unusual thinking or delusions for a clinical trial to improve symptoms. Participants take add-on d-cycloserine or placebo while receiving twelve weeks of cognitive behavior therapy and are compensated for their time.

Eligibility:

  • 18 - 68 years old

  • Diagnosed with Schizophrenia or Schizoaffective Disorder 

Faith Dickerson, PhD, MPH

Sheppard Pratt Health System Towson, MD

(Coordinating site: New York University School of Medicine)

Click here to visit clinicaltrials.gov for more information

Cassie Stallings, R.N. or call 410-938-4356

Dementia

This study is currently recruiting participants.

Population:
Adults age 50 to 85

Setting:
Outpatient

This is a 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.


Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Jennifer Sklar or call 410-938-3136

Depression

This study is currently recruiting participants.

Population:
Adolescents/young adults age 12-21

Setting:
Outpatient

This study's purpose is to evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Jennifer Sklar or call 410-938-3136

Major Depressive Disorder

This study is currently recruiting participants.

Population: Adults age 22 to 65

Setting: Outpatient

This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression who have failed to respond to at least one (1) antidepressant medication. Patients will be randomly assigned to either active or sham therapy and will undergo daily treatments for a period of time. Following completion of blinded treatments, patients may be eligible for a course of open label treatments.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Marylu Ortiz or call 410-938-3135

Bipolar Disorder

This study is currently recruiting participants.

Population: Adults age 18+

Setting: Outpatient

This study is an Open-Label study of Transcranial Magnetic Stimulation (TMS) in patients with Bipolar Disorder who are currently depressed.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Jennifer Sklar or call 410-938-3136

Major Depressive Disorder

This study is currently recruiting participants.

Population: Adolescents age 12-17

Setting: Inpatient/Outpatient

The purpose of this study is to assess the efficacy of a single (first) dose of three fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information.

Jennifer Sklar or call 410-938-3136

Major Depressive Disorder

This study is currently recruiting participants.

Population: Adults age 18-64

Setting: Inpatient/Outpatient

The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information.

Jennifer Sklar or call 410-938-3136.

If you are interested in participating in one of the above studies, please email or call the contact listed next to the studies we are actively recruiting for or complete the adjacent form to submit your contact information.

Interested in a Clinical Trial?

Select the study in which you are interested below: